About this Journal Submit a Manuscript Table of Contents 
Oxidative Medicine and Cellular Longevity
Volume 2011 (2011), Article ID 139194, 10 pages
doi:10.1155/2011/139194
Research Article

Cyclosporine A in Ullrich Congenital Muscular Dystrophy: Long-Term Results

Luciano Merlini,1,2 Patrizia Sabatelli,3 Annarita Armaroli,1 Saverio Gnudi,4 Alessia Angelin,5 Paolo Grumati,6 Maria Elena Michelini,7 Andrea Franchella,7 Francesca Gualandi,1 Enrico Bertini,8 Nadir Mario Maraldi,2 Alessandra Ferlini,1 Paolo Bonaldo,6 and Paolo Bernardi5

1Section of Medical Genetics, Department of Experimental and Diagnostic Medicine, University of Ferrara, 44121 Ferrara, Italy
2Laboratorio Di Biologia Cellulare Muscoloscheletrica, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
3Istituto di Genetica Molecolare, CNR, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
4Medicina Generale, Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
5Department of Biomedical Sciences, University of Padova, 35121 Padova, Italy
6Department of Histology, Microbiology and Medical Biotechnology, University of Padova, 35121 Padova, Italy
7Pediatric Surgery Department, Sant’Anna Hospital, Corso Giovecca 203, 44121 Ferrara, Italy
8Unit for Neuromuscular Disorders, Department of Neurosciences and Laboratory of Molecular Medicine, Bambino Gesu’ Children’s Research Hospital, 00165 Roma, Italy

Received 19 May 2011; Revised 9 August 2011; Accepted 11 August 2011

Academic Editor: Jing Yi

Copyright © 2011 Luciano Merlini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bethlem and G. K. Van Wijngaarden, “Benign myopathy, with autosomal dominant inheritance: a report on three pedigrees,” Brain, vol. 99, no. 1, pp. 91–100, 1976. View at Scopus
  2. O. C. Vanegas, E. Bertini, R. Z. Zhang et al., “Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7516–7521, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. L. Merlini, E. Martoni, P. Grumati et al., “Autosomal recessive myosclerosis myopathy is a collagen VI disorder,” Neurology, vol. 71, no. 16, pp. 1245–1253, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. Merlini, L. Morandi, C. Granata, and A. Ballestrazzi, “Bethlem myopathy: early-onset benign autosomal dominant myopathy with contractures. Description of two new families,” Neuromuscular Disorders, vol. 4, no. 5-6, pp. 503–511, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Pepe, B. Giusti, E. Bertini et al., “A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the α1(VI) collagen chain in an Italian family affected by Bethlem myopathy,” Biochemical and Biophysical Research Communications, vol. 258, no. 3, pp. 802–807, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. G. Pepe, E. Bertini, P. Bonaldo et al., “Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23-24 November 2001, Naarden, NLD,” Neuromuscular Disorders, vol. 12, no. 10, pp. 984–993, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Nadeau, M. Kinali, M. Main et al., “Natural history of Ullrich congenital muscular dystrophy,” Neurology, vol. 73, no. 1, pp. 25–31, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. K. Lampe, K. M. Flanigan, and K. M. Bushby, “Collagen type VI-related disorders,” GeneReview, 2007, http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=bethlem#bethlem.
  9. F. Gualandi, A. Urciuolo, E. Martoni et al., “Autosomal recessive Bethlem myopathy,” Neurology, vol. 73, no. 22, pp. 1883–1891, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. K. Lampe and K. M. D. Bushby, “Collagen VI related muscle disorders,” Journal of Medical Genetics, vol. 42, no. 9, pp. 673–685, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. P. Bonaldo, P. Braghetta, M. Zanetti, S. Piccolo, D. Volpin, and G. M. Bressan, “Collagen VI deficiency induces early onset myopathy in the mouse: An animal model for Bethlem myopathy,” Human Molecular Genetics, vol. 7, no. 13, pp. 2135–2140, 1998. View at Scopus
  12. W. A. Irwin, N. Bergamin, P. Sabatelli et al., “Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency,” Nature Genetics, vol. 35, no. 4, pp. 367–371, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Bernardi, A. Krauskopf, E. Basso et al., “The mitochondrial permeability transition from in vitro artifact to disease target,” FEBS Journal, vol. 273, no. 10, pp. 2077–2099, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Angelin, T. Tiepolo, P. Sabatelli et al., “Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 3, pp. 991–996, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. L. Merlini, A. Angelin, T. Tiepolo et al., “Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5225–5229, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. EMEA, “Guideline on clinical trials in small populations,” 2006, http://www.ema.europa.eu/.
  17. L. Merlini, E. S. Mazzone, A. Solari, and L. Morandi, “Reliability of hand-held dynamometry in spinal muscular atrophy,” Muscle and Nerve, vol. 26, no. 1, pp. 64–70, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. L. Merlini, E. Bertini, C. Minetti et al., “Motor function-muscle strength relationship in spinal muscular atrophy,” Muscle and Nerve, vol. 29, no. 4, pp. 548–552, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. L. Merlini, A. Solari, G. Vita et al., “Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study,” Journal of Child Neurology, vol. 18, no. 8, pp. 537–541, 2003. View at Scopus
  20. R. Geiger, A. Strasak, B. Treml et al., “Six-minute walk test in children and adolescents,” Journal of Pediatrics, vol. 150, no. 4, pp. 395–399, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. Rosenfeld and C. E. Jackson, “Quantitative assessment and outcome measures in neuromuscular disease,” in Neuromuscular Disorders in Clinical Practice, B. Katirji, H. J. Kaminski, D. C. Preston, R. L. Ruff, and B. E. Shapiro, Eds., pp. 309–343, Butterworth-Heinemann, Boston, Mass, USA, 2002.
  22. J. R. Zanchetta, H. Plotkin, and M. L. Alverez Filgueira, “Bone mass in children: normative values for the 2-20-year-old population,” Bone, vol. 16, supplement 4, pp. 393S–399S, 1995. View at Publisher · View at Google Scholar · View at Scopus
  23. CDC: centers for disease control and prevention, “BMI-for-age growth charts,” http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html.
  24. S. Sartore, L. Gorza, and S. Schiaffino, “Fetal myosin heavy chains in regenerating muscle,” Nature, vol. 298, no. 5871, pp. 294–296, 1982. View at Scopus
  25. S. Schiaffino, L. Gorza, and I. Dones, “Fetal myosin immunoreactivity in human dystrophic muscle,” Muscle and Nerve, vol. 9, no. 1, pp. 51–58, 1986. View at Scopus
  26. S. Ciciliot and S. Schiaffino, “Regeneration of mammalian skeletal muscle: basic mechanisms and clinical implications,” Current Pharmaceutical Design, vol. 16, no. 8, pp. 906–914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Suzuki, A. Hase, B. Yoon Kim et al., “Up-regulation of glial cell line-derived neurotrophic factor (GDNF) expression in regenerating muscle fibers in neuromuscular diseases,” Neuroscience Letters, vol. 257, no. 3, pp. 165–167, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. A. G. Engel and G. Biesecker, “Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers,” Annals of Neurology, vol. 12, no. 3, pp. 289–296, 1982. View at Scopus
  29. A. Angelin, P. Bonaldo, and P. Bernardi, “Altered threshold of the mitochondrial permeability transition pore in Ullrich congenital muscular dystrophy,” Biochimica et Biophysica Acta, vol. 1777, no. 7-8, pp. 893–896, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. P. Bernardi, L. Scorrano, R. Colonna, V. Petronilli, and F. Di Lisa, “Mitochondria and cell death. Mechanistic aspects and methodological issues,” European Journal of Biochemistry, vol. 264, no. 3, pp. 687–701, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Feutren and M. J. Mihatsch, “Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases,” New England Journal of Medicine, vol. 326, no. 25, pp. 1654–1660, 1992.
  32. B. Nashan, A. Bock, J. L. Bosmans et al., “Use of neoral C2 monitoring: a European consensus,” Transplant International, vol. 18, no. 7, pp. 768–778, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. E. A. C. Beenakker, J. H. Van der Hoeven, J. M. Fock, and N. M. Maurits, “Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry,” Neuromuscular Disorders, vol. 11, no. 5, pp. 441–446, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Allamand, L. Merlini, and K. Bushby, “166th ENMC International Workshop on collagen type VI-related myopathies, 22-24 May 2009, Naarden, The Netherlands,” Neuromuscular Disorders, vol. 20, no. 5, pp. 346–354, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. I. Higuchi, T. Horikiri, T. Niiyama et al., “Pathological characteristics of skeletal muscle in Ullrich's disease with collagen VI deficiency,” Neuromuscular Disorders, vol. 13, no. 4, pp. 310–316, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J. D. Cook and D. S. Glass, “Strength evaluation in neuromuscular disease,” Neurologic Clinics, vol. 5, no. 1, pp. 101–123, 1987. View at Scopus
  37. L. Merlini and P. Bernardi, “Therapy of collagen VI-related myopathies (Bethlem and Ullrich),” Neurotherapeutics, vol. 5, no. 4, pp. 613–618, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. W. Bohannon, “Results of resistance exercise on a patient with amyotrophic lateral sclerosis. A case report,” Physical Therapy, vol. 63, no. 6, pp. 965–968, 1983. View at Scopus
  39. P. B. Kang, A. T. Kho, D. Sanoudou et al., “Variations in gene expression among different types of human skeletal muscle,” Muscle and Nerve, vol. 32, no. 4, pp. 483–491, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. L Merlini, “Measuring muscle strength in clinical trials,” The Lancet Neurology, vol. 9, no. 12, pp. 1146–1147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. A. -C. Söderpalm, P. Magnusson, A.-C. Åhlander et al., “Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy,” Neuromuscular Disorders, vol. 17, no. 11-12, pp. 919–928, 2007. View at Publisher · View at Google Scholar · View at PubMed
  42. P. C. Scacheri, E. M. Gillanders, S. H. Subramony et al., “Novel mutations in collagen VI genes: expansion of the Bethlem myopathy phenotype,” Neurology, vol. 58, no. 4, pp. 593–602, 2002. View at Scopus
  43. M. J. Hansson, G. Mattiasson, R. Månsson et al., “The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria,” Journal of Bioenergetics and Biomembranes, vol. 36, no. 4, pp. 407–413, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. P. Grumati, L. Coletto, P. Sabatelli et al., “Autophagy is defective in collagen VI muscular dystrophies, and its reactivation rescues myofiber degeneration,” Nature Medicine, vol. 16, no. 11, pp. 1313–1320, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. A. M. Tolkovsky, “Autophagy thwarts muscle disease,” Nature Medicine, vol. 16, no. 11, pp. 1188–1190, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus